Mesoblast Limited - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
MESO Nasdaq 2836 www.mesoblast.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Mesoblast Limited

Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch - Jul 29th, 2026 6:57 pm
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy? - Jul 17th, 2026 10:00 am
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain - Jul 13th, 2026 6:35 pm
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Amid Renewed US-Iran Tensions Ahead of Q2 Earnings Season - Jul 10th, 2026 7:07 am
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 - Jul 9th, 2026 6:30 pm
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs - Jun 30th, 2026 6:38 pm
Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility - Jun 24th, 2026 6:59 pm
Kina Securities And 2 Other Stocks That May Be Trading Below Their Estimated Value On The ASX - Jun 11th, 2026 1:35 pm
ASX Growth Companies With High Insider Ownership - May 31st, 2026 1:38 pm
ASX Penny Stocks With Market Caps Under A$3B To Consider - May 27th, 2026 9:05 pm
ASX Stocks Trading At An Estimated Discount Of Up To 45.8% Below Intrinsic Value - May 13th, 2026 1:34 pm
How Completion Of RMAT Phase 3 Enrollment At Mesoblast (ASX:MSB) Has Changed Its Investment Story - May 1st, 2026 4:19 pm
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million - Apr 29th, 2026 6:55 pm
ASX Penny Stocks To Watch In April 2026 - Apr 29th, 2026 2:02 pm
ASX Growth Companies With High Insider Ownership In April 2026 - Apr 29th, 2026 1:38 pm
Assessing Mesoblast’s Valuation After Recent Share Price Weakness And Conflicting Growth Signals - Apr 28th, 2026 8:08 pm
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain - Apr 28th, 2026 6:53 pm
Mesoblast Ltd (MESO): Secure Exclusive Rights to a Vital Platform - Apr 28th, 2026 11:30 am
Why Mesoblast Limited (MESO) is One of the Best Low Priced Biotech Stocks to Invest in - Apr 19th, 2026 6:11 pm
Mesoblast Limited (MESO), One of the Best Long-Term ASX Stocks To Buy Right Now; See Why - Apr 19th, 2026 11:35 am